HIF-alpha Stabilizing Compounds for Endogenous EPO Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anemia and ischemic disorders are inadequate, and recombinant erythropoietin therapy is costly and inconvenient, with existing therapies failing to directly address tissue damage caused by hypoxia and ischemia.
Innovation Solution
Development of novel compounds represented by specific formulas that modulate hypoxia-inducible factor (HIF) and/or endogenous erythropoietin (EPO) to treat and prevent HIF-associated and EPO-associated disorders, including anemia and ischemia, through administration of specific pharmaceutical compounds and compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant erythropoietin therapy is used to treat anemia, then erythropoietin levels are increased, but treatment cost increases and administration convenience decreases
Solution Approach 1:
The patent employs small molecule compounds that selectively stabilize HIF-alpha to trigger endogenous erythropoietin production, allowing the body's own systems to generate the therapeutic agent rather than requiring external administration of recombinant EPO. This self-service approach eliminates the need for frequent injections and reduces treatment costs while maintaining effective erythropoietin levels.
2Reliability
If current anemia therapies are used, then treatment is provided, but they fail to directly address tissue damage caused by hypoxia and ischemia
Solution Approach 1:
The patent uses HIF-alpha stabilizing compounds to preemptively activate protective gene expression programs before irreversible tissue damage occurs. By stabilizing HIF-alpha under hypoxic conditions, the therapy triggers early protective responses including erythropoietin production and angiogenesis, addressing tissue damage before it becomes severe rather than treating only the anemia symptoms.
3Quantity of substance
If HIF-alpha is stabilized under normoxic conditions, then endogenous erythropoietin production increases, but protein stability mechanisms normally degrade HIF-alpha
Solution Approach 1:
The patent employs small molecule compounds that alter the stability parameter of HIF-alpha protein, preventing its normal degradation by the proteasome pathway under normoxic conditions. These compounds bind to HIF-alpha and protect it from ubiquitination and proteasomal degradation, thereby stabilizing the protein and enabling continuous endogenous erythropoietin production without requiring hypoxic conditions.
Data Source
AI summary
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.